Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Myelodysplastic Syndromes 17Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Hodgkin Disease 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia, Lymphocytic, Chronic, B-Cell 10Myeloproliferative Disorders 9Melanoma 8Recurrence 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Biphenotypic, Acute 7Anemia, Refractory, with Excess of Blasts 7Lymphoma 6Leukemia 6Lymphoma, Mantle-Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Waldenstrom Macroglobulinemia 4Neuroblastoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Juvenile 4Hematologic Neoplasms 4Colorectal Neoplasms 4Burkitt Lymphoma 4Uveal Melanoma 3Stomach Neoplasms 3Primary Myelofibrosis 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

Injections 2Gemtuzumab 2Decitabine 2Cytarabine 2fludarabine phosphate 1Idarubicin 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Daunorubicin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × fludarabine phosphate × 90 days × Clear all
NCT00801489 2026-03-30

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Recruiting
270 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡